icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
 
 
 
Favorable Preclinical Profile of IDX21437, a Novel Uridine Nucleotide Prodrug, for Use in a Direct-Acting Antiviral (DAA) Regimen for HCV
 
 
  Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C - (04/07/14)
 
Reported by Jules Levin
EASL April 9-13, 2014, London, UK
 
K Gupta1, M Seifer1, I Serra1, H Rashidzadeh1, S Luo1, M La Colla1, X-R Pan-Zhou1, C Chapron1, B Hernandez-Santiago1, C Parsy2, F-R Alexandre2, B Mayes1, S Bhadresa1, A Moussa1, R Rush1 1 Idenix Pharmaceuticals, Inc., Cambridge, MA, USA; 2Idenix Medicinal Chemistry Research Laboratory, Montpellier, France.

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif